New gout pill BR2251 enters Mid-Stage trial
NCT ID NCT07498647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests BR2251, a new daily tablet, in 160 adults with gout and high uric acid. Participants receive one of three doses of BR2251 or the standard drug febuxostat for 12 weeks. The goal is to see which dose best lowers uric acid levels and reduces gout flare-ups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BR2251 tablets
- What this could lead to
- If successful, BR2251 could offer a new daily pill option to lower uric acid and reduce gout attacks.
- What could go wrong
- This is an early Phase 2 dose-finding study with only 160 participants. It may not show clear benefit or could have side effects not yet seen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT AND HYPERURICEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.